Physician profile
Nitasa Sahu
NPI 1548673585
$3,654.39
in general payments reported to CMS, 2019-2025
28 companies · $1,530 in 2025
The $1,530 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $356 · 2023: $521 · 2024: $1,116 · 2025: $1,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,845 · Travel and Lodging: $208 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,845.23 |
| Travel and Lodging | $207.90 |
| Education | $114.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $621.68 | 2023-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $478.86 | 2021-2025 | Tyvaso, Tyvaso, Remodulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.41 | 2022-2025 | Spiriva Respimat, Stiolto Respimat |
| Olympus Corporation of The Americas | $226.38 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $218.45 | 2023-2025 | Glassia, Aralast |
| Astrazeneca Pharmaceuticals LP | $186.29 | 2024-2025 | Tezspire, Fasenra |
| Pulmonx Corporation | $183.99 | 2024-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Astellas Pharma US INC | $169.35 | 2025 | Cresemba |
| Mylan Specialty L.P. | $144.64 | 2023-2024 | Yupelri |
| Medtronic, INC. | $125.00 | 2023 | Harmony |
| Regeneron Healthcare Solutions, INC. | $124.74 | 2022 | |
| Merck Sharp & Dohme LLC | $114.31 | 2024-2025 | Winrevair |
| Genzyme Corporation | $111.13 | 2023-2025 | |
| Viatris Specialty LLC | $101.43 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $77.15 | 2023-2025 | Uptravi, Opsumit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $76.34 | 2022 | |
| Vifor Pharma, INC. | $70.01 | 2024 | Zemaira, Veltassa |
| Atricure, INC. | $53.26 | 2023 | |
| La Jolla Pharmaceutical Company | $39.46 | 2023-2025 | Giapreza |
| Insmed, INC. | $33.32 | 2023 | Arikayce |
| Pfizer INC. | $33.17 | 2024 | |
| 3b Medical, INC. | $30.81 | 2024 | Luna |
| Bayer Healthcare Pharmaceuticals INC. | $30.51 | 2025 | |
| Electromed, INC. | $29.98 | 2022 | |
| Baxter Healthcare | $23.49 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Mallinckrodt Hospital Products INC. | $15.07 | 2023 | Acthar |
| Philips North America LLC | $14.77 | 2023 | |
| Ani Pharmaceuticals, INC. | $13.39 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitasa Sahu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.